Disease Area
Cancer Biomarker Research
Prevena Health is investigating circulating molecular signals associated with tumor biology. Our platform aims to support earlier awareness of oncologic change through continuous, non-invasive biomarker surveillance.
Our Approach
Exploring continuous molecular surveillance for oncology research.
Many cancers develop over months or years before clinical symptoms emerge. During this window, molecular changes may be occurring at levels below the threshold of conventional testing. Prevena Health is exploring whether continuous biomarker surveillance may help surface these subtle shifts earlier.
Our platform is being developed to continuously sample and quantify circulating molecular analytes through a skin-worn sensor and multiplexed assay cartridge. In the oncology context, this approach aims to support researchers and clinicians investigating multi-cancer early detection by providing longitudinal biomarker trend data rather than single-point snapshots.
Rather than replacing established screening protocols, Prevena is designed to offer a complementary layer of molecular intelligence that may support more proactive clinical conversations about cancer risk.
Key Biomarkers
Circulating analytes associated with oncologic biology.
ctDNA (Circulating Tumor DNA)
Fragments of tumor-derived DNA circulating in the bloodstream, associated with tumor presence and genomic alterations. Prevena is investigating ctDNA as part of multi-analyte detection research.
CA-125
A protein biomarker associated with ovarian and other gynecologic cancers. Longitudinal trends in CA-125 levels may provide additional context beyond single-point measurements.
PSA (Prostate-Specific Antigen)
A protein associated with prostate tissue activity. Continuous monitoring of PSA trends may offer additional temporal context for research into prostate-related change.
CEA (Carcinoembryonic Antigen)
A glycoprotein associated with several cancer types, including colorectal. CEA trend analysis is being explored as part of multi-marker approaches to cancer signal research.
AFP (Alpha-Fetoprotein)
A protein associated with liver and germ cell tumors. Monitoring AFP trajectories over time may contribute to broader panels aimed at multi-organ cancer research.
Exosomes & Circulating Tumor Cells
Extracellular vesicles and intact tumor cells circulating in biological fluids. These analytes are associated with tumor activity and are being explored as complementary signals in multi-cancer research.
Why It Matters
Why earlier awareness may matter in oncology.
Cancer is often identified at advanced stages. Many cancers are not detected until they have progressed beyond localized disease, when treatment options may be more limited and outcomes less favorable.
Earlier molecular signals may precede clinical symptoms. Research suggests that tumor-associated biomarkers may become detectable in circulation before conventional imaging or symptom-based detection identifies disease.
Multi-cancer early detection is an active research area. The concept of screening for multiple cancer types through a single blood-based approach is the subject of significant ongoing clinical investigation worldwide.
Longitudinal trends may add context. A single biomarker measurement provides a snapshot; continuous monitoring may reveal trajectories and rate-of-change patterns that add clinical research value.
Prevena Health's platform is in development and is not commercially available. It has not been cleared, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. It is not a diagnostic device. Content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment.
Partner with us on cancer biomarker research.
We are seeking clinical and research collaborators to advance multi-cancer early detection through continuous molecular surveillance.
Partner With Us